About 25% of U.S. healthcare spending — between $760 billion and $935 billion annually — is wasted, according to a new report published today. Researchers from Humana (NYSE:HUM) and the University of Pittsburgh School of Medicine searched medical literature from January 2012 to May 2019, looking for waste and savings opportunities in six domains of […]
HHS proposes regulatory changes to promote value-based payment arrangements
UPDATED Oct. 9, 2019, with comments from press briefing in Minneapolis. The U.S. Department of Health and Human Services today proposed what it’s describing as a modernization of the physician self-referral law in order to promote value-based healthcare. The proposed regulatory changes, which are heading into a 75-day public comment period, say the physician self-referral […]
How can medical device companies thrive in the future?
Medical device data is becoming more important than the hardware itself, so medtech companies need to forge a partnership with consumer technology companies to stay innovative, according to a new report from Deloitte. The Deloitte report — called “Winning the Future of Medtech” — came out yesterday in advance of next week’s AdvaMed MedTech Conference […]
Baxter throws $500m behind CMS push for dialysis innovation
Baxter (NYSE:BAX) officials apparently think their company can benefit from a Trump administration and CMS proposal to provide extra reimbursement for new and innovative dialysis equipment and supplies. Just days ago, CEO Joe Almeida told analysts in an earnings call that the company planned to invest $500 million to significantly increase production capacity and meet new […]
Medicare’s bundled ortho payments yield modest savings
Medicare’s randomized trial of a new bundled payment model for hip and knee replacement surgeries led to $812 in savings per procedure, a 3.1% reduction in costs when compared with traditional means of paying for care, according to new research. The study from Harvard T.H. Chan School of Public Health and Harvard Medical School found that the […]
Nearly 150 groups join AdvaMed’s anti medtech tax letter
In a recent letter sent to leaders of U.S.Congress and Senate, medtech industry lobbying group AdvaMed was joined by 142 other organizations in urging for the repeal of the 2.3% medical device tax. Major medical companies including Medtronic (NYSE:MDT), BD (NYSE:BDX), Boston Scientific (NYSE:BSX) and GE Healthcare (NYSE:GE) added their signatures to the letter, as well as a […]
Gingrich stumps for medical device tax repeal
Former U.S. House Speaker Newt Gingrich this week published an editorial with StatNews urging members of Congress to repeal the medical device tax. In the opinion piece, Gingrich calls the tax “misguided” and “job-killing” and suggested that the 2.3% tax, which was levied on medical devices as part of the Affordable Care Act in 2010, […]
Medtech reporting would change under new opioid law
A section of the recently-passed bill to address the opioid crisis could have implications for medtech. The 250-page Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act) contains a provision that would require manufacturers of certain medical devices, drugs and biologics covered by Medicare, Medicaid, […]
Report: Trump to sign controversial law granting patients access to experimental drugs
President Donald Trump is slated to approve legislation this week that will give terminally-ill patients access to experimental drugs that haven’t yet been cleared by the FDA. The “right-to-try” bill has sparked a great deal of controversy among policymakers and patient groups. While some, including the president, describe the effort as offering hope to patients […]
HHS secretary calls on drug companies to ‘stop the price hikes’
After President Donald Trump’s drug pricing speech last week was deemed a “non-event” by analysts, all eyes turned to the secretary of the U.S. Dept. of Health & Human Services, Alex Azar, to see what the former pharma executive viewed as the administration’s top concerns. Azar called on the industry to “stop the price hikes” […]
Trump’s drug pricing plan called ‘non-event’ by analysts
President Donald Trump last week unveiled his administration’s plan to lower drug prices. But investors seemed relieved after the president made his highly anticipated announcement – stocks for large pharmaceutical companies and middlemen, like pharmacy benefit managers, were up on Friday. Trump did not commit to follow through with promises he made while campaigning for […]
- 1
- 2
- 3
- …
- 74
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube